MARKET

PLSE

PLSE

Pulse
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.81
-0.90
-6.12%
After Hours: 13.81 0 0.00% 16:43 10/19 EDT
OPEN
14.81
PREV CLOSE
14.71
HIGH
15.09
LOW
13.61
VOLUME
83.81K
TURNOVER
--
52 WEEK HIGH
17.77
52 WEEK LOW
5.11
MARKET CAP
348.18M
P/E (TTM)
-5.9411
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)
Benzinga · 10/06 12:24
WWR, MYOK, EPR and FCEL among midday movers
Gainers: Greenpro Capital (GRNQ) +85%.MyoKardia (MYOK) +58%.Westwater Resources (WWR) +53%.Eidos Therapeutics (EIDX) +40%.Scully Royalty (SRL) +34%.Enlivex Therapeutics (ENLV) +28%.Humanigen (HGEN) +24%.Corvus Pharmaceuticals (CRVS) +22%.Piedmont Lithium (PLL) +22%.Pulse Biosciences (PLSE) +22%.Losers: Nam Tai
Seekingalpha · 10/05 16:42
Pulse Biosciences receives MDSAP certification
Pulse Biosciences ([[PLSE]] +0.7%) announces the receipt of Medical Device Single Audit Program certification.The program allows the conduct of a single regulatory audit of a medical device manufacturer’s quality management system."On
Seekingalpha · 09/29 13:48
Pulse Biosciences Grants Equity Incentive Awards To New Employees
Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse Biosciences" or the "Company") a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock
Business Wire · 09/15 20:14
Pulse Biosciences to Participate in the H.C. Wainwright Global Investment Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to virtually participate in the upcoming H.C. Wainwright Global Investment Conference.
Business Wire · 09/01 21:05
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings:Pulse Biosciences (PLSE): $250M.ContraFect (CFRX): $150M.Larimar Therapeutics (LRMR): $200M.
Seekingalpha · 08/15 22:07
Pulse Biosciences reports Q2 results
Pulse Biosciences (NASDAQ:PLSE): Q2 GAAP EPS of -$0.53. Cash, cash equivalents and investments totaled $37.8M. Press Release
seekingalpha · 08/11 01:27
Pulse Biosciences Q2 EPS $(0.53) Misses $(0.50) Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.50) by 6 percent. This is a 3.64 percent increase over losses of $(0.55) per share from
Benzinga · 08/10 20:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLSE. Analyze the recent business situations of Pulse through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PLSE stock price target is 16.00 with a high estimate of 16.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 62
Institutional Holdings: 3.00M
% Owned: 11.89%
Shares Outstanding: 25.21M
TypeInstitutionsShares
Increased
27
618.51K
New
12
113.66K
Decreased
6
7.64K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-2.39%
Healthcare Equipment & Supplies
-1.40%
Key Executives
Chairman/Independent Director
Robert Duggan
President/Chief Executive Officer/Director
Darrin Uecker
Chief Financial Officer/Executive Vice President - Finance/Treasurer/Secretary
Sandra Gardiner
Executive Vice President/General Manager
Edward Ebbers
Independent Director
Kenneth Clark
Independent Director
Mitchell Levinson
Independent Director
Manmeet Soni
Independent Director
Mahkam Zanganeh
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PLSE
Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Pulse Biosciences Inc stock information, including NASDAQ:PLSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLSE stock methods without spending real money on the virtual paper trading platform.